Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

3 Predictions for Advanced Micro Devices in 2026: https://g.foolcdn.com/editorial/images/854459/man-looking-in-the-distance-with-a-pair-of-binoculars.jpg
3 Predictions for Advanced Micro Devices in 2026

It's been a disappointing past few months for shareholders in Advanced Micro Devices (NASDAQ: AMD). After soaring in early October on news that the company will be supplying processing chips for

Palantir Has a Vision of an AI-First World. Will It Make Investors Rich?: https://g.foolcdn.com/editorial/images/857041/aistocksimage-green.png
Palantir Has a Vision of an AI-First World. Will It Make Investors Rich?

Palantir Technologies (NASDAQ: PLTR) has become one of the most popular stocks in the market. Like many such stocks, Palantir has been volatile, rising and falling with prevailing sentiment among

Naya Capital Adds Masimo Shares: https://cdn.content.foolcdn.com/images/1umn9qeh/production/f5acfa2370b69ef05efd688fbbc9e56e546c0092-1401x1251.png?rect=76,0,1251,1251&w=384&h=384&q=75&fit=crop&auto=format
Naya Capital Adds Masimo Shares

According to an SEC filing dated Feb. 18, Naya Capital Management UK Ltd disclosed a new position in Masimo (NASDAQ:MASI), acquiring nearly 1.6 million shares.

Masimo is a leading provider of

2 Dividend Stocks to Hold for the Next 5 Years: https://g.foolcdn.com/editorial/images/856026/pipeline-green-grass.jpg
2 Dividend Stocks to Hold for the Next 5 Years

What will the world look like five years from now? How you answer the question should help you determine how you invest now.

I expect that healthcare and energy will remain critical in 2031. That's

Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer: https://cdn.content.foolcdn.com/images/1umn9qeh/production/dbf4812d84ab78c74b512c7cb2e4d70bee11215c-1401x1251.png?rect=76,0,1251,1251&w=384&h=384&q=75&fit=crop&auto=format
Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer

ImmunityBio (NASDAQ:IBRX), which develops immunotherapies and vaccines for cancers and infectious diseases, closed Wednesday at $8.54, up 41.86%. The stock jumped after the European Commission

What Is One of the Best Healthcare Stocks to Own for the Next 10 Years?: https://g.foolcdn.com/editorial/images/855684/cancer-patient-consultation-home-visit.jpg
What Is One of the Best Healthcare Stocks to Own for the Next 10 Years?

The past 12 months haven't been kind to UnitedHealth Group's (NYSE: UNH) stock, which is down over 41% (as of Feb. 16). There are a few reasons for its struggles, including disappointing earnings

Why ImmunityBio Stock Is Soaring Today: https://g.foolcdn.com/editorial/images/856858/break-through-ceiling.jpg
Why ImmunityBio Stock Is Soaring Today

Wednesday's trading session is proving to be a thrilling one for ImmunityBio (NASDAQ: IBRX) shareholders. As of 1:50 p.m. ET today the biopharma stock is up an incredible 33.1%. The reason

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought: https://g.foolcdn.com/editorial/images/856793/gettyuparrowcelebration.jpeg
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

It's been a rough start in 2026 for Ark Invest co-founder, CEO, and Chief Investment Officer Cathie Wood. The largest exchange-traded fund at her company is trading 10% lower year to date. The

Some People Think This AI Stock Is Evil -- But It Has Been Wildly Successful Financially: https://g.foolcdn.com/editorial/images/856821/crystal-ball-getty.jpg
Some People Think This AI Stock Is Evil -- But It Has Been Wildly Successful Financially

As an investor, you always have the right to bring your own values into your investing decisions. Some investors avoid companies in certain industries because of their personal concerns. In some

UnitedHealth Group Faces New Challenges -- What Investors Need to Know: https://g.foolcdn.com/editorial/images/856061/gettyimages-903626078.jpg
UnitedHealth Group Faces New Challenges -- What Investors Need to Know

Last year was a difficult one for UnitedHealth Group (NYSE: UNH). The biggest health insurer in the U.S. came up against a number of headwinds -- from an ever-changing healthcare landscape to the

6 Forever Dividend Stocks: https://g.foolcdn.com/editorial/images/856575/gettyimages-1924765911.jpg
6 Forever Dividend Stocks

Regardless of whether you are looking at a growth stock or dividend stock, cash flow is key. However, when analyzing the safety and reliability of a dividend, cash flow is a must.

In today's video

Should You Buy Shares of CRISPR Therapeutics in February?: https://g.foolcdn.com/editorial/images/856324/crsp.jpg
Should You Buy Shares of CRISPR Therapeutics in February?

Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer and various genetic conditions is an obvious home run. CRISPR Therapeutics

Is a Dividend Cut Coming for UnitedHealth Stock?: https://g.foolcdn.com/editorial/images/856011/question-mark-made-of-money.jpg
Is a Dividend Cut Coming for UnitedHealth Stock?

Things have gone from bad to worse for UnitedHealth Group (NYSE: UNH). Last year, the giant health insurer suspended its guidance due to higher-than-expected medical costs. The company replaced its

Vertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market Crash: https://g.foolcdn.com/editorial/images/854936/gettyimages-research-team-smiles-in-lab.jpg
Vertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market Crash

Vertex Pharmaceuticals (NASDAQ: VRTX) hasn't made the headlines in recent times like companies involved in high-growth areas such as weight loss drugs or artificial intelligence (AI). But this

Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash: https://cdn.content.foolcdn.com/images/1umn9qeh/production/5a835a403d8e07011d119675ff444b39fb510d2f-1401x1251.png?rect=76,0,1251,1251&w=384&h=384&q=75&fit=crop&auto=format
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash

On February 17, 2026, Rock Springs Capital Management LP disclosed in an SEC filing that it sold 159,379 shares of Agios Pharmaceuticals (NASDAQ:AGIO) in the fourth quarter, an estimated $5.59

Is Nvidia Still a Millionaire-Maker?: https://g.foolcdn.com/editorial/images/856624/gettyimages-519517489-1.jpg
Is Nvidia Still a Millionaire-Maker?

Investors who got in on Nvidia (NASDAQ: NVDA) stock a few years ago have seen their returns multiply. The stock has climbed 700% over the past three years as the artificial intelligence (AI)

IRadimed Stock Up 80% in One Year as Fund Sells $29 Million Stake Amid Record Quarter: https://cdn.content.foolcdn.com/images/1umn9qeh/production/5a835a403d8e07011d119675ff444b39fb510d2f-1401x1251.png?rect=76,0,1251,1251&w=384&h=384&q=75&fit=crop&auto=format
IRadimed Stock Up 80% in One Year as Fund Sells $29 Million Stake Amid Record Quarter

On February 17, 2026, Nine Ten Capital Management disclosed selling 342,907 shares of IRadimed (NASDAQ:IRMD), an estimated $29.42 million trade based on quarterly average pricing.

According to a

1 Reason I'd Buy Eli Lilly Stock and Never Sell: https://g.foolcdn.com/editorial/images/854973/gettyimages-1768385129.jpg
1 Reason I'd Buy Eli Lilly Stock and Never Sell

Investing in pharmaceutical stocks can be tricky. Drugmakers put an enormous amount of time and money into research and development of new products. It takes more than 10 years to develop a new drug

How Palantir Is Becoming an AI Giant: https://g.foolcdn.com/editorial/images/856704/submarine-getty.jpg
How Palantir Is Becoming an AI Giant

In the past 25 years, software capabilities have advanced at a breakneck pace. The sheer amount of information that businesses, government agencies, and other entities have gathered encompasses the

EQS-Adhoc: Bayer Aktiengesellschaft: Monsanto announces Roundup™ class settlement agreement  to resolve current and future claims
EQS-Adhoc: Bayer Aktiengesellschaft: Monsanto announces Roundup™ class settlement agreement to resolve current and future claims
EQS-Adhoc: Bayer Aktiengesellschaft: Monsanto announces Roundup™ class settlement agreement to resolve current and future claims
2026 Could Be a Big Year for Viking Therapeutics. Time to Buy?: https://g.foolcdn.com/editorial/images/856623/gettyimages-two-people-smile-as-they-look-at-a-tablet.jpg
2026 Could Be a Big Year for Viking Therapeutics. Time to Buy?

Viking Therapeutics (NASDAQ: VKTX) is aiming to join one of the biggest growth industries of the times: the weight loss drug market. People hoping to lose weight have rushed to get in on GLP-1

The Best Stocks to Invest $1,000 in This February: https://g.foolcdn.com/editorial/images/856111/healthcare.jpg
The Best Stocks to Invest $1,000 in This February

It seems as though every industry outside of artificial intelligence (AI) is in the dumps. Even health insurance stocks had one of the wildest years in the sector's history in 2025. Why? Because of

Chemed Stock Down 15% in a Year as One Fund Builds a $5.56 Million Stake: https://cdn.content.foolcdn.com/images/1umn9qeh/production/ad04e80951d6de292a5f59f60fce986c74bc8b4f-1401x1251.png?rect=76,0,1251,1251&w=384&h=384&q=75&fit=crop&auto=format
Chemed Stock Down 15% in a Year as One Fund Builds a $5.56 Million Stake

On February 12, 2026, Barington Companies Management disclosed a new position in Chemed (NYSE:CHE), acquiring 13,000 shares in an estimated $5.56 million trade.

According to an SEC filing dated

EQS-News: Newron Secures Up to EUR 38 Million to Advance  Phase III Evenamide Program
EQS-News: Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
EQS-News: Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
Prediction: Micron's Stock Price Will Be Worth This Much by the End of 2026: https://g.foolcdn.com/editorial/images/856259/micron-technology-building-with-micon-logo-on-sign-and-building_micron-5.jpg
Prediction: Micron's Stock Price Will Be Worth This Much by the End of 2026

Smart investors already know that the artificial intelligence (AI) revolution has served as a generational bellwether for semiconductor stocks. Over the last few years, capital expenditure budgets